Side-by-side · Research reference
ARA 290vsCagrilintide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BPhase 3HUMAN-REVIEWED35/64 cited
01Mechanism of Action
Parameter
ARA 290
Cagrilintide
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Feedback intact?
N/A — does not interact with hematopoietic EPO receptorLiu 2014
Yes — acts via physiological amylin pathways
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Antibody development
Not reported in clinical trials
—
02Dosage Protocols
Parameter
ARA 290
Cagrilintide
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
Once weekly (subcutaneous)Bailey 2026
Long-acting formulation.
Duration
28 days (Phase 2)Culver 2017
Corneal nerve improvements observed by day 28.
26–52 weeks in trialsYamauchi 2026
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Timing
Any time of day
No circadian dependence reported.
—
Standard dose (combination)
—
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
Monotherapy dosing
—
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
Cagrilintide
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
Predominant fat loss with weight reduction
Weight loss vs semaglutide
—
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
Absolute weight change
—
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
Glycemic benefit
—
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
Mitochondrial function
—
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
Key publications
—
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
04Side Effects & Safety
Parameter
ARA 290
Cagrilintide
Injection site reaction
Mild, transient
—
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Tolerability
Well-tolerated in Phase 2 trialsCulver 2017Brines 2015
Tolerability considerations similar to GLP-1RAs
Gastrointestinal
—
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
Injection site reactions
—
Local reactions possible with subcutaneous administration
Safety profile
—
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
Muscle preservation
—
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
05Administration Protocol
Parameter
ARA 290
Cagrilintide
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation